Ozempic and Mounjaro Linked to Hair Loss: What the Research Actually Says
A wave of new studies flags alopecia as an emerging signal in GLP-1 users — here's what's driving it and what you can do.
I have everything I need. Let me now write the article.
Hair loss wasn't on anyone's radar when they started Ozempic or Mounjaro. Nausea, yes. Constipation, sure. But waking up to a pillow full of hair? That one catches people off guard — and this week, the research conversation got louder.
A ScienceDaily report published July 24, 2026 — echoed by Sky News and Female First — tied semaglutide (Ozempic) and tirzepatide (Mounjaro) to a higher risk of alopecia. Here's what the peer-reviewed literature actually says, what the FDA labels do and don't tell you, and what it might mean for you.
What the studies found
This isn't a one-off anecdote. Multiple research teams have now looked at this.
A 2025 retrospective cohort study in the Journal of the American Academy of Dermatology examined GLP-1 receptor agonist use and hair loss directly — one of the more rigorous designs available because it compares real patient records rather than just counting complaint reports. A 2026 systematic review in the International Journal of Dermatology specifically examined the effects of GLP-1 receptor agonists on both hair loss and regrowth. A separate 2025 systematic review in Cureus focused on hair loss associated with GLP-1 receptor agonist use broadly, and a 2025 scoping review also in Cureus flagged alopecia as an "emerging adverse effect" specifically in people using these drugs for weight loss.
The pattern across this body of work: hair shedding appears to be a real, documented signal — not just social media noise.
The FDA labels don't list it — here's why that matters
Worth being precise here: hair loss is not listed as an adverse reaction in either the FDA's official Ozempic label or the FDA's official Mounjaro label. Both labels list nausea, diarrhea, vomiting, decreased appetite, constipation, and abdominal pain as the most common adverse reactions (those occurring in ≥5% of patients in clinical trials).
That absence doesn't mean it isn't happening — it means it wasn't captured at high enough rates in the original trials to make the label. Post-market research is exactly how these signals get identified. The FDA's MedWatch system exists precisely for this reason, and researchers are now mining that data alongside electronic health records.
So why does the hair fall out?
The leading explanation isn't that the drug itself is toxic to hair follicles. It's something called telogen effluvium — a well-recognized form of temporary hair shedding triggered by physical stress on the body. MedlinePlus (NIH) notes that stress, low protein intake, and poor nutrition are all established causes of hair loss.
Rapid, significant caloric restriction — which is exactly what GLP-1 drugs produce in many people — can push a large number of hair follicles into their resting (telogen) phase simultaneously. Two to four months later, those hairs shed all at once. The good news built into this mechanism: it's typically temporary, and regrowth often follows once the body stabilizes.
A 2025 analysis in the Journal of Drugs in Dermatology looking at cutaneous adverse reactions across GLP-1 therapies reinforces that the skin and hair effects being reported may be tied to the metabolic and nutritional changes these drugs cause — not necessarily a direct pharmacological action on hair follicles.
What you can actually do about it
If you're on a GLP-1 medication and noticing more hair in your brush, a few things are worth discussing with your prescriber or a dermatologist:
Protein intake. MedlinePlus specifically flags low protein diet as a cause of hair loss. GLP-1 drugs suppress appetite significantly, which can make hitting protein targets harder. If your intake has dropped, that's a concrete, addressable factor.
Nutritional status. Iron, zinc, and biotin deficiencies can all accelerate shedding. A basic lab panel can tell you where you stand — and it's a reasonable ask if you're losing weight quickly.
Timing context. If the shedding started two to four months after you began the medication or after a period of fast weight loss, telogen effluvium is a plausible explanation. That timeline is characteristic of the condition.
Don't stop your medication without talking to your prescriber first. Hair shedding is distressing, but it's typically temporary. Abruptly stopping a GLP-1 drug has its own consequences that need to be weighed.
What this means for you
- Hair loss is an emerging, research-documented signal in GLP-1 users — but it's not confirmed as a direct drug effect and is more likely tied to rapid weight loss and reduced caloric intake.
- Neither the Ozempic nor Mounjaro FDA label currently lists alopecia as an adverse reaction, which means you may need to proactively raise this with your prescriber if it's happening to you.
- Protecting protein intake and monitoring nutritional status are practical, evidence-adjacent steps you can take right now — and both are worth a conversation with your care team.
Not medical advice. Talk to your prescriber about your specific situation, symptoms, and whether any changes to your treatment plan make sense for you.
